GGrantIndex
← Leaderboards

Robert H Brown

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$15,031,077
Attributed
$18,744,849
Total exposure
15
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.1M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$23,984,819 · 16

By mechanism

R01$10,703,154 · 5
P01$5,527,207 · 4
RC2$3,608,339 · 1
U01$1,389,945 · 1
P50$1,328,586 · 1
RC1$999,599 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Amyotrophic Lateral Sclerosis”

Research focus

Amyotrophic Lateral SclerosisGenesNeurodegenerative DisordersMouse ModelToxic EffectIn VivoMotor NeuronsPhenotypeInsightMutationLeadMutantProteinsMediatingWild Type MouseNerve DegenerationPharmaceutical PreparationsTransgenic MiceGeneticCellsSafetySuperoxide DismutasePropertyIn Vitro

Grant awards (51)

Multi-Targeting Oligonucleotide Therapeutics for Familial and Sporadic Amyotrophic Lateral Sclerosis$665,737
R01 · FY2025 · NS
Multi-Targeting Oligonucleotide Therapeutics for Familial and Sporadic Amyotrophic Lateral Sclerosis$665,737
R01 · FY2024 · NS
Next-generation antisense therapeutics for ALS and frontotemporal dementia$635,090
R01 · FY2023 · NS
Next-generation antisense therapeutics for ALS and frontotemporal dementia$635,090
R01 · FY2022 · NS
Next-generation antisense therapeutics for ALS and frontotemporal dementia$635,090
R01 · FY2021 · NS
Next-generation antisense therapeutics for ALS and frontotemporal dementia$635,090
R01 · FY2020 · NS
Next-generation antisense therapeutics for ALS and frontotemporal dementia$660,421
R01 · FY2019 · NS
Silencing C9or72 with rAAV Mediated RNAi$464,134
R01 · FY2017 · NS · contact PI
Silencing C9or72 with rAAV Mediated RNAi$360,494
R01 · FY2016 · NS · contact PI
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1$430,747
R01 · FY2015 · NS · contact PI
Silencing C9or72 with rAAV Mediated RNAi$360,494
R01 · FY2015 · NS · contact PI
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1$485,765
R01 · FY2014 · NS · contact PI
Silencing C9or72 with rAAV Mediated RNAi$377,369
R01 · FY2014 · NS · contact PI
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1$479,028
R01 · FY2013 · NS · contact PI
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1$539,080
R01 · FY2012 · NS · contact PI
Dysferlin: Approaches to Domain Analysis and Gene Therapy$332,508
P50 · FY2011 · NS · contact PI
Development of New Therapeutics for Amyotrophic Lateral Sclerosis$1
U01 · FY2011 · NS · contact PI
Full Human Genome Sequencing in ALS$1,803,930
RC2 · FY2010 · NS · contact PI
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis$499,740
RC1 · FY2010 · NS
Dysferlin: Approaches to Domain Analysis and Gene Therapy$329,932
P50 · FY2010 · NS · contact PI
Development of New Therapeutics for Amyotrophic Lateral Sclerosis$1
U01 · FY2010 · NS · contact PI
Full Human Genome Sequencing in ALS$1,804,409
RC2 · FY2009 · NS · contact PI
High-Throughput Genomic Approaches to Identify ALS Genes$509,876
R01 · FY2009 · NS · contact PI
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis$499,859
RC1 · FY2009 · NS
Dysferlin: Approaches to Domain Analysis and Gene Therapy$335,683
P50 · FY2009 · NS · contact PI
Development of New Therapeutics for Amyotrophic Lateral Sclerosis$1
U01 · FY2009 · NS · contact PI
High-Throughput Genomic Approaches to Identify ALS Genes$495,019
R01 · FY2008 · NS · contact PI
Development of New Therapeutics for Amyotrophic Lateral Sclerosis$471,756
U01 · FY2008 · NS · contact PI
Dysferlin: Approaches to Domain Analysis and Gene Therapy$330,463
P50 · FY2008 · NS · contact PI
Development of New Therapeutics for Amyotrophic Lateral Sclerosis$157,252
U01 · FY2008 · NS · contact PI
CLINICAL TRIAL: PYRIMETHAMINE FOR TREATMENT OF SOD1 MEDIATED AMYLOTROPHIC LATERA$1,619
M01 · FY2008 · RR · contact PI
Development of New Therapeutics for Amyotrophic Lateral Sclerosis$760,934
U01 · FY2007 · NS · contact PI
High-Throughput Genomic Approaches to Identify ALS Genes$495,008
R01 · FY2007 · NS · contact PI
Dysferlin: Approaches to Domain Analysis and Gene Therapy$287,237
P01 · FY2007 · NS · contact PI
PYRIMETHAMINE FOR TREATMENT OF SOD1 MEDIATED AMYLOTROPHIC LATERAL SCLEROSIS$7,394
M01 · FY2007 · RR · contact PI
High-Throughput Genomic Approaches to Identify ALS Genes$494,943
R01 · FY2006 · NS · contact PI
A Screen For Modulators of Membrane Repair in Normal and Dystrophic Muscle$187,976
R21 · FY2006 · AR · contact PI
High-Throughput Genomic Approaches to Identify ALS Genes$529,594
R01 · FY2005 · NS
A Screen For Modulators of Membrane Repair in Normal and Dystrophic Muscle$231,000
R21 · FY2005 · AR
OXIDATIVE AND EXCITATORY TOXICITY IN NEURODEGENERATION$1,085,629
P01 · FY2004 · AG
OXIDATIVE AND EXCITATORY TOXICITY IN NEURODEGENERATION$1,060,670
P01 · FY2003 · AG
OXIDATIVE AND EXCITATORY TOXICITY IN NEURODEGENERATION$1,036,445
P01 · FY2002 · AG
IDENTIFICATION OF GENE DEFECTS CAUSING ALS-FTD$0
P01 · FY2002 · AG
CORE--MOLECULAR GENETICS$0
P01 · FY2002 · AG
OXIDATIVE AND EXCITATORY TOXICITY IN NEURODEGENERATION$1,012,922
P01 · FY2001 · AG
CORE--MOLECULAR GENETICS$0
P01 · FY2001 · AG
IDENTIFICATION OF GENE DEFECTS CAUSING ALS-FTD$0
P01 · FY2001 · AG
OXIDATIVE AND EXCITATORY TOXICITY IN NEURODEGENERATION$1,044,304
P01 · FY2000 · AG
PATHOGENESIS OF ALS IN SOD1 TRANSGENIC MICE$149,348
R01 · FY2000 · NS
CORE--MOLECULAR GENETICS$0
P01 · FY2000 · AG
IDENTIFICATION OF GENE DEFECTS CAUSING ALS-FTD$0
P01 · FY2000 · AG